Structural basis of leukotriene B4 receptor 1 activation

Na Wang, Xinheng He, Jing Zhao, Hualiang Jiang, Xi Cheng, Xia Yu, H. Eric Xu, Yuanzheng HeNature Communications 2022 · DOI

Abstract

Leukotriene B4 receptor 1 (BLT1) plays crucial roles in the acute inflammatory responses and is a valuable target for anti-inflammation treatment, however, the mechanism by which leukotriene B4 (LTB4) activates receptor remains unclear. Here, we report the cryo-electron microscopy (cryo-EM) structure of the LTB4-bound human BLT1 in complex with a G<sub>i</sub> protein in an active conformation at resolution of 2.91 Å. In combination of molecule dynamics (MD) simulation, docking and site-directed mutagenesis, our structure reveals that a hydrogen-bond network of water molecules and key polar residues is the key molecular determinant for LTB4 binding. We also find that the displacement of residues M101<sup>3.36</sup> and I271<sup>7.39</sup> to the center of receptor, which unlock the ion lock of the lower part of pocket, is the key mechanism of receptor activation. In addition, we reveal a binding site of phosphatidylinositol (PI) and discover that the widely open ligand binding pocket may contribute the lack of specificity and efficacy for current BLT1-targeting drug design. Taken together, our structural analysis provides a scaffold for understanding BLT1 activation and a rational basis for designing anti-leukotriene drugs.

Introduction

Inflammation is a vital immune response, but its dysregulation leads to chronic diseases such as arthritis, asthma, and atherosclerosis. The BLT1 receptor is a primary "on-switch" for white blood cells (neutrophils and macrophages) in response to the lipid mediator LTB4. While BLT1 is a high-value drug target, designing effective treatments has been challenging; most candidates fail in clinical trials due to low efficacy or poor specificity. Until now, structural knowledge was limited to the receptor's inactive state. Without seeing the receptor in its active state, the precise molecular movements that translate LTB4 binding into a cellular signal remained unknown.

Structural Determination of the Active BLT1 Complex

To address this, researchers employed cryo-electron microscopy (cryo-EM) to determine the structure of the human BLT1-$G_i$ complex at a sharp 2.91 Å resolution. This high-resolution blueprint provides the first clear look at the active conformation of the receptor.

Cryo-EM density map of the LTB4-bound BLT1-Gi complex showing the ligand (magenta) nestled within the receptor pocket.

The study integrated structural data with molecular dynamics (MD) simulations and site-directed mutagenesis to validate the functional relevance of the observed interactions. The coordinates and density maps have been deposited in public repositories (PDB: 7VKT; EMDB: EMD-32018).

Molecular Determinants of LTB4 Binding and Activation

A key finding of this work is the unique way LTB4 interacts with BLT1. Unlike many G protein-coupled receptors (GPCRs) where the ligand makes direct contact with the protein, LTB4 relies on a sophisticated hydrogen-bond network of water molecules and polar residues (such as R156 and R267) to "lock" into the pocket. Mutagenesis confirmed that these residues are essential, as their alteration almost completely abolished the receptor's ability to respond to LTB4.

The transition to the active state is driven by a novel "ion lock" mechanism. The displacement of two specific residues, M101 and I271, toward the center of the receptor unlocks the lower pocket, allowing the $G_i$ protein to dock and initiate signaling. This activation is further characterized by a 5.7 Å outward displacement of Transmembrane Helix 6 (TM6), a hallmark of GPCR activation.

Discovery of a Novel Lipid Binding Site

The structural analysis also revealed an unexpected binding site for phosphatidylinositol (PI) on the intracellular side of the receptor. Mass spectrometry confirmed the presence of specific PI species (18:0/16:1 and 18:0/18:1) associated with the receptor.

Ribbon representation of the BLT1-Gi complex highlighting the phosphatidylinositol (PI) binding site at the receptor-membrane interface.

This discovery suggests that the local lipid environment of the cell membrane might directly tune how the receptor signals, although the exact biological function of this lipid interaction remains a subject for future study.

Implications for Drug Design

One of the most significant insights for pharmacology is the observation of a "widely open" extracellular binding pocket. Unlike other lipid receptors that possess a "lid" or "cap" to sequester ligands, the BLT1 pocket is unusually exposed. This lack of structural constraint likely explains why current drugs lack specificity—they allow too much solvent interference or fail to stay securely in the pocket. Future drug design will need to focus on creating bulkier or more specialized ligands that can better occupy this cavernous space to achieve the specificity needed for safe anti-inflammatory therapies.

In summary, this structural analysis provides a long-awaited scaffold for understanding BLT1 activation and a rational basis for designing the next generation of anti-leukotriene drugs.

Summary updated

Abstract

Leukotriene B4 receptor 1 (BLT1) plays crucial roles in the acute inflammatory responses and is a valuable target for anti-inflammation treatment, however, the mechanism by which leukotriene B4 (LTB4) activates receptor remains unclear. Here, we report the cryo-electron microscopy (cryo-EM) structure of the LTB4 -bound human BLT1 in complex with a G<sub>i</sub> protein in an active conformation at resolution of 2.91 Å. In combination of molecule dynamics (MD) simulation, docking and site-directed mutagenesis, our structure reveals that a hydrogen-bond network of water molecules and key polar residues is the key molecular determinant for LTB4 binding. We also find that the displacement of residues M101<sup>3.36</sup> and I271<sup>7.39</sup> to the center of receptor, which unlock the ion lock of the lower part of pocket, is the key mechanism of receptor activation. In addition, we reveal a binding site of phosphatidylinositol (PI) and discover that the widely open ligand binding pocket may contribute the lack of specificity and efficacy for current BLT1-targeting drug design. Taken together, our structural analysis provides a scaffold for understanding BLT1 activation and a rational basis for designing anti-leukotriene drugs.
BibTeX
@inproceedings{wang2022structural,
  author = {Na Wang and Xinheng He and Jing Zhao and Hualiang Jiang and Xi Cheng and Xia Yu and H. Eric Xu and Yuanzheng He},
  title = {{Structural basis of leukotriene B4 receptor 1 activation}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-28820-9},
}
Figure